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After the publication of this article \[[@CR1]\], we were made aware that the osmolarity of aflibercept (Eylea) was incorrect and should have been 286 mOsm and not 1000 mOsm. The correct version of Table 1 is shown in this correction (Table [1](#Tab1){ref-type="table"}).Table 1The formulations and pH values of anti-VEGF agentsDrugConcentration (osmolarity)Dose in the vitreous (4 ml)/dose in 0.002 mlFormulationMeasured pH95% CIRanibizumab (Lucentis)10 mg/ml (289 mOsm)0.5 mg/0.02 mg10 mM histidine-HCl, 10% α,α-trehalose dihydrate, 0.01% polysorbate 205.325.0--5.63Bevacizumab (Avastin)25 mg/ml (182 mOsm)1.25 mg/0.05 mg42 mM NaH~2~PO~4~·H~2~O, 8.45 mM Na~2~HPO~4~, 6% α,α-trehalose dihydrate, 0.04% polysorbate 205.915.63--6.19Aflibercept (Eylea)40 mg/ml (286 mOsm)2 mg/0.08 mg10 mM Na~3~PO~4~, 40 mM NaCl, 5% sucrose, 0.03% polysorbate 206.055.78--6.31Ziv-aflibercept (Zaltrap)25 mg/ml (1000 mOsm)1.25 mg/0.05 mg100 mM NaCl, 5 mM Na citrate, 5 mM Na~3~PO~4~, 20% sucrose, 0.1% polysorbate 206.16.05--6.15Rituximab (Rituxan)10 mg/ml1 mg/0.02 mg154 mM NaCl, 25 mM Na citrate·2 H~2~O, 0.07% polysorbate 806.295.97--6.61

The online version of the original article can be found under doi:10.1186/s40942-017-0075-x.
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